Frontline T cell-redirecting therapies in newly diagnosed multiple myeloma: key signals from the 2025 ASH Annual Meeting.

IF 17.5 1区医学 Q1 HEMATOLOGY

Experimental Hematology & Oncology Pub Date : 2026-07-20 DOI:10.1186/s40164-026-00809-w

Huixing Zhou, Xiaoyun Jin, Wenming Chen, Hong-Hu Zhu, Wen Gao

引用次数: 0

Abstract

Early frontline data presented at the 2025 ASH Annual Meeting suggest that T cell-redirecting strategies, including chimeric antigen receptor (CAR)-T cells and bispecific antibodies (BsAbs), can induce rapid, high rates of minimal residual disease (MRD)-negative responses in newly diagnosed multiple myeloma (NDMM), including transplant-ineligible (TI) and high-risk populations. However, short follow-up, heterogeneous MRD methodologies, and infection risk-particularly with continuous bispecific exposure-underscore that these approaches remain investigational and should be advanced through randomized, MRD-guided fixed-duration trials.

查看原文本刊更多论文

新诊断多发性骨髓瘤的一线T细胞重定向疗法：来自2025年ASH年会的关键信号

在2025年ASH年会上公布的早期一线数据表明，T细胞重定向策略，包括嵌合抗原受体(CAR)-T细胞和双特异性抗体（BsAbs），可以在新诊断的多发性骨髓瘤（NDMM）中诱导快速、高比例的最小残留病（MRD）阴性反应，包括移植不符合条件（TI）和高危人群。然而，短期随访、异质MRD方法和感染风险（特别是连续双特异性暴露）强调，这些方法仍处于研究性阶段，应该通过随机、MRD指导的固定时间试验来推进。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Experimental Hematology & Oncology Medicine-Oncology

CiteScore

12.60

自引率

7.30%

发文量

审稿时长

6 weeks

期刊介绍： Experimental Hematology & Oncology is an open access journal that encompasses all aspects of hematology and oncology with an emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings. Experimental Hematology & Oncology publishes original work, hypothesis, commentaries and timely reviews. With open access and rapid turnaround time from submission to publication, the journal strives to be a hub for disseminating new knowledge and discussing controversial topics for both basic scientists and busy clinicians in the closely related fields of hematology and oncology.